NK & CAR-NK Cells
Scale allogeneic NK and CAR-NK therapies from 60 mL to 80 L, with cytotoxic potency intact and perfusion built in.
NK cells are a promising allogeneic immunotherapy with less cytokine-release risk than CAR-T, but traditional autologous platforms cannot reach commercial allogeneic scale. Vertical-Wheel® bioreactors span a wide working-volume range for parallel optimization and scale-up.
Gentle mixing maintains cytotoxic potency, matching or exceeding static G-Rex in head-to-head expansion.
One platform spans 60 mL to 80 L for parallel process optimization and commercial allogeneic supply.
Integrates Repligen XCell® ATF perfusion for high-density CAR-NK expansion at 3 L and beyond.
What You Can Build.
Workflows our customers and collaborators run on the Vertical-Wheel® platform, every one backed by published data or a protocol below.
- NK expansion
- CAR-NK
- Allogeneic immunotherapy
- Perfusion culture
- NK-derived EVs
Vertical-Wheel® matched or exceeded static G-Rex cytotoxic potency while scaling NK expansion from 60 mL to 80 L.
The Evidence for NK cells.
Application notes, protocols and peer-reviewed data with tangible results in Vertical-Wheel® bioreactors, leading with the studies that show real numbers.
Ready to Scale Your NK cells Process?
Talk to an application scientist about a Vertical-Wheel® path tuned to your cell type and timeline.